News
News
サブ-ナビゲーション
information
現在位置:
News
Corporate Guide
Business
Investor Relations
Sustainability
Contact Us
News
Latest
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
All
IR情報
Clear All
All
決算
業績
適時開示
PR
IR
ガバナンス
株主総会
有価証券報告書
その他
IRトピックス
IR情報
サステナビリティ
Clear All
All
サステナビリティ
Sustainability
ニュース
Clear All
All
ニュースリリース
PR・その他
お知らせ
News
Clear All
All
News Release
Other
Information
Clear All
Results
20
of
194
2025/03/28
IR情報
IR
[Delayed] Notice Concerning the Absorption-type Merger (Simplified Merger) of the Wholly Owned Subsidiary
（267KB）
2025/02/13
IR情報
IR
Notice Concerning Revisions to the Financial Results Forecasts
（182KB）
2025/02/13
IR情報
IR
Consolidated Financial Results for the Nine Months Ended December 31, 2024 (Under Japanese GAAP)
（431KB）
2025/01/27
IR情報
IR
Notice Concerning Acquisition of Shares of ViSpot, Inc. (to Make It a Subsidiary)
（220KB）
2025/01/15
IR情報
IR
Notice Concerning Acquisition of Shares of Curio Bioscience, Inc. (to Make It a Subsidiary)
（245KB）
2024/11/08
IR情報
IR
Notice Concerning Differences between the Financial Forecast and the Actual Results
（209KB）
2024/11/08
IR情報
IR
Consolidated Financial Results for the Six Months Ended September 30, 2024 (Under Japanese GAAP)
（443KB）
2024/08/08
IR情報
IR
Consolidated Financial Results for the Three Months Ended June 30, 2024 (Under Japanese GAAP)
（233KB）
2024/07/31
IR情報
IR
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2024
（1,059KB）
2024/06/27
IR情報
IR
Matters Concerning Controlling Shareholders
（184KB）
2024/06/27
News
News Release
Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
2024/05/28
IR情報
IR
Notice of the 22nd Annual General Meeting of Shareholders
（201KB）
2024/05/10
IR情報
IR
Notice Concerning Dividends from Surplus
（139KB）
2024/05/10
IR情報
IR
Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (Under Japanese GAAP)
（445KB）
2024/02/14
IR情報
IR
Consolidated finacial results for the nine months ended Dec 31(Under Japanese GAAP)
（368KB）
2023/11/13
News
News Release
Takara Bio Announces "SonuAAV™", a Novel AAV Vector for Efficient Gene Transfer to the Inner Ear Organ.
2023/11/09
IR情報
IR
Notice Concerning Differences between the Financial Results Forecasts and the Actual Results
（163KB）
2023/11/09
IR情報
IR
Notice Concerning Revisions to the Financial Results Forecasts
（177KB）
2023/11/09
IR情報
IR
Consolidated Financial Results for the Six Months Ended September 30, 2023 (Under Japanese GAAP)
（427KB）
2023/10/12
News
News Release
Construction of the Center for Cell and Gene Processing III, which manufactures mRNA vaccine ingredients and enzymes for mRNA production
2023/10/05
News
News Release
Takara Bio Announces Publication of Results from NY-ESO-1・siTCR™ Gene Therapy Study in Clinical Cancer Research
2023/10/03
News
News Release
Takara Bio Announces Presentation of Comparability Studies for CD19 JAK/STAT CAR-T Cell Technology Transfer
2023/09/25
News
News Release
Takara Bio enters into a license agreement of RetroNectin® with Fondazione Telethon ETS
2023/08/30
IR情報
IR
{Delayed] Corporate Governance Report
（1,523KB）
2023/08/08
IR情報
IR
Consolidated Financial Results for the Three Months Ended June 30, 2023 (Under Japanese GAAP)
（424KB）
2023/08/08
IR情報
IR
Notice Concerning Revisions to the First Half Financial Results Forecasts
（179KB）
2023/08/01
News
News Release
Started using refrigerated boxes for transportation with consideration for the environment
2023/07/31
IR情報
IR
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2023
（1,551KB）
2023/06/29
IR情報
IR
Matters Concerning Controlling Shareholders
（241KB）
2023/05/29
News
News Release
Takara Bio Announces Poster Presentation of Data from Clinical Trial of NY-ESO-1・siTCR™ Gene Therapy at ASCO2023
2023/05/11
IR情報
IR
Notice Concerning Dividends from Surplus
（232KB）
2023/05/11
IR情報
IR
Takara Bio Group Formulated “Medium-Term Management Plan 2026”
（350KB）
2023/05/11
IR情報
IR
Consolidated Financial Results for the Fiscal Year Ended March 31, 2023 (Under Japanese GAAP)
（610KB）
2023/04/19
News
News Release
Indian subsidiary acquires ISO13485 certification
2023/04/03
News
News Release
Takara Bio Announces Initiation of Clinical Trial for Next-Generation CAR-T therapy
2023/03/02
IR情報
IR
ARTICLES OF INCORPORATION
（111KB）
2023/02/09
IR情報
IR
Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts （Dividend Increase）
（252KB）
2023/02/09
IR情報
IR
Consolidated Financial Results for the Nine Months Ended December 31, 2022（Under Japanese GAA）
（456KB）
2023/01/25
IR情報
IR
[Delayed]Takara Bio Announces Transfer of SAKIGAKE and Orphan Designations for NY-ESO-1/siTCR Gene Therapy Product
（229KB）
2022/11/10
News
News Release
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for NY-ESO-1・siTCR™ gene therapy candidate
2022/11/10
IR情報
IR
Notice Concerning Revisions to the Financial Results Forecasts and Dividend Forecasts (Dividend Increase)
（186KB）
2022/11/10
IR情報
IR
Consolidated Financial Results for the Six Months Ended September 30, 2022 (Under Japanese GAAP)
（404KB）
2022/10/25
IR情報
IR
Notice Concerning Revisions to the First Half Financial Results Forecasts
（244KB）
2022/09/16
IR情報
IR
[Correction] Annual Securities Report for the Fiscal Year Ended March 31, 2022
（212KB）
2022/09/08
News
News Release
Launched CDMO service for gene therapy products using siTCR® technology or JAK/STAT technology
2022/09/06
IR情報
IR
Annual Report 2022
（8,041KB）
2022/08/29
IR情報
IR
[Delayed] Annual Securities Report for Fiscal Year Ended March 31, 2022
（1,191KB）
2022/08/04
IR情報
IR
Consolidated Financial Results for the Three Months Ended June 30, 2022 (Under Japanese GAAP)
（394KB）
2022/07/22
News
News Release
Launched a CDMO service using CereAAV™, a brain-tropic AAV vector for gene therapy
2022/07/06
IR情報
IR
[Delayed] Corporate Governance Report
（770KB）
2022/06/13
IR情報
IR
Notice of the 20th Annual General Meeting of Shareholders
（208KB）
2022/06/01
News
News Release
Takara Bio to Present Clinical Data from Investigator-Initiated Trial in Canada of NY-ESO-1・siTCR™ Gene Therapy at ASCO2022 【Poster Posted】
2022/05/12
IR情報
IR
Notice of Dividends of Surplus
（135KB）
2022/05/12
IR情報
IR
Consolidated Financial Statements for the Year Ended March 31, 2022 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]
（350KB）
2022/04/25
News
News Release
Takara Bio Announces a Novel Brain-Tropic AAV Vector "CereAAV™" for Gene Therapy
2022/02/10
IR情報
IR
Notice Concerning Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（250KB）
2022/02/10
IR情報
IR
Consolidated Financial Statements for the Third Quarter Ended December 31, 2021 FY2022 (April 1, 2021-March 31, 2022) [UNAUDITED]
（771KB）
2022/01/24
IR情報
IR
Notice Concerning Recording of Extraordinary Gains and Losses Related to Subsidization
（248KB）
2022/01/20
IR情報
IR
[Delayed] Corporate Governance Report
（768KB）
2021/12/02
News
News Release
Implementation of the Center for Gene and Cell Processing to Respond to Diverse Modalities and Develop Supply Chains
2021/11/09
News
News Release
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Otsuka Pharmaceutical Co., Ltd. for Oncolytic virus HF10 and CD19-targeted CAR Gene Therapies
2021/11/09
IR情報
IR
Notice of Revisions of Financial Forecast and Dividend Forecast (Dividend Increase)
（138KB）
2021/11/09
IR情報
IR
Consolidated Financial Statements for the Second Quarter Ended September 30, 2021 FY2022 (April 1, 2021 - March 31, 2022) [UNAUDITED]
（339KB）
2021/10/21
IR情報
IR
Notice of Revision of Financial Forecast
（241KB）
2021/09/21
IR情報
IR
Notice of Resolution of the Board of Directors on Selection of “Prime Market” Listing on the Tokyo Stock Exchange under the New Market Segments
（224KB）
2021/08/06
IR情報
IR
[Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED]
（596KB）
2021/08/06
IR情報
IR
[Updated] Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 - June 30, 2021) [UNAUDITED]
（154KB）
2021/08/03
IR情報
IR
Notice of Revision of Financial Forecast and Dividend Forecast (Dividend Increase)
（139KB）
2021/08/03
IR情報
IR
Consolidated Financial Statements for the First Quarter Ended June 30, 2021 FY2022 (April 1, 2021 － June 30, 2021) 〔UNAUDITED〕
（596KB）
2021/06/21
News
News Release
Takara Bio enters into a license and supply agreement of RetroNectin® with BioNTech Cell & Gene Therapies GmbH
2021/05/13
IR情報
IR
Consolidated Financial Statements for the Year Ended March 31, 2021 FY2021 (April 1, 2020 - March 31, 2021) [UNAUDITED]
（695KB）
2021/02/10
IR情報
IR
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（287KB）
2021/02/10
IR情報
IR
Consolidated Financial Statements for the Third Quarter Ended December 31, 2020 FY2021 (April 1, 2020 - March 31, 2021)［UNAUDITED］
（915KB）
2021/02/01
News
News Release
Takara Bio Acquires ISO13485 Certification
2021/01/05
IR情報
IR
Corporate Governance Report
（681KB）
2020/11/25
IR情報
IR
We have posted "Financial Results Presentation".
（1,020KB）
2020/11/10
IR情報
IR
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（217KB）
2020/11/10
IR情報
IR
Consolidated Financial Statements for the Second Quarter Ended September 30, 2020 FY2021 (April 1, 2020 - September 30, 2020) [UNAUDITED]
（681KB）
2020/11/06
IR情報
IR
We have issued "Annual Report 2020".
（1,023KB）
2020/10/21
IR情報
IR
【Delayed】Announcement on Revision of Financial Forecast
（225KB）
2020/08/05
IR情報
IR
【Delayed】Announcement on revision of financial forecast
（369KB）
2020/08/05
IR情報
IR
【Delayed】Consolidated Financial Statements for the First Quarter Ended June 30, 2020 FY2021 (April 1, 2020 - June 30, 2020)
（780KB）
2020/08/04
IR情報
IR
Summary of Financial Results for the first quarter 2021
（366KB）
2020/08/04
IR情報
IR
Takara Bio terminates the license agreement relating to Oncolytic Virus C-REV with Tasly Biopharmaceuticals, China
（285KB）
2020/06/26
IR情報
IR
We have posted "Financial Results Presentation".
（670KB）
2020/06/24
News
News Release
Clinical program for NY-ESO-1・siTCR(TM) gene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
2020/06/08
IR情報
IR
Takara Bio Group’s Formulation of Long-Term Management Plan FY2026 and Medium-Term Management Plan FY2023
（994KB）
2020/05/28
IR情報
IR
Notice of the 18th Annual General Meeting of Shareholders
（163KB）
2020/05/19
IR情報
IR
【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2020 FY2020 (April 1, 2019 -March 31, 2020)[UNAUDITED]
（710KB）
2020/05/14
IR情報
IR
Summary of Financial Results 2020
（430KB）
2020/05/13
IR情報
IR
【Delayed】Takara Bio has entered into a license agreement relating to C-REV with Tasly Biopharmaceuticals, China
（227KB）
2020/03/06
News
News Release
Takara Bio to Support Development of Novel Coronavirus VaccineUndertaken by Osaka University Group
2020/02/13
IR情報
IR
Consolidated Financial Statements for the Third Quarter Ended December 31, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（625KB）
2020/01/21
News
News Release
Takara Bio Launches a New Facility for the Research and Manufacturing of Regenerative Medicine Products
2020/01/16
News
News Release
Takara Bio and Tmunity Enter into License Agreement to Advance siRNA Technology to Improve T cell Therapies
2019/11/21
IR情報
IR
We have posted "financial results presentation".
（551KB）
2019/11/12
IR情報
IR
Consolidated Financial Statements for the Second Quarter Ended September 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（626KB）
2019/09/27
IR情報
IR
Strategic Change in Development of Oncolytic Virus Immunotherapy C-REV
（247KB）
2019/09/27
IR情報
IR
We have issued "Annual Report 2019".
（1,044KB）
2019/09/24
News
News Release
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1・siTCR Gene Therapy at ESMO 2019
2019/08/14
IR情報
IR
Corporate Governance Report
（514KB）
2019/08/06
IR情報
IR
Consolidated Financial Statements for the First Quarter Ended June 30, 2019 FY2020 (April 1, 2019 - March 31, 2020)[UNAUDITED]
（583KB）
2019/05/30
IR情報
IR
Notice of the 17th Annual General Meeting of Shareholders
（148KB）
2019/05/22
IR情報
IR
We have posted "Financial Results Presentation".
（820KB）
2019/05/16
News
News Release
Takara Bio to Present Clinical Data of Oncolytic Virus C-REV and NY-ESO-1・siTCR Gene Therapy at ASCO 2019
2019/05/14
IR情報
IR
Consolidated Financial Statements for the Year Ended March 31, 2019 FY2019 (April 1, 2018 - March 31, 2019)［UNAUDITED］
（795KB）
2019/05/14
IR情報
IR
Summary of Financial Results 2019
（399KB）
2019/05/07
News
News Release
A wholly-owned subsidiary, Takara Biotechnology (Dalian) Co., Ltd. Acquires ISO:13485 certification
2019/04/26
News
News Release
Takara Bio to Acquire an Exclusive License to Use Patent Technology Relating to New Generation CAR Gene Therapy
2019/04/26
News
News Release
Joint Research on New Development of CAR Gene Therapy with Mie University
2019/04/24
News
News Release
Joint Research on Novel Approach to Cancer Immune and Gene Therapy with Department of Immunotherapeutics, The University of Tokyo Hospital
2019/04/03
News
News Release
Takara Bio Submits Drug Master File to the U.S. FDA for RetroNectin® GMP grade (Solution Type)
2019/03/29
IR情報
IR
Marketing Authorization Application for Oncolytic Virus Immunotherapy C-REV for Unresectable or Metastatic Melanoma Submitted in Japan
（194KB）
2019/02/15
News
News Release
Designation Description Change of NY-ESO-1・siTCR gene therapy product under “SAKIGAKE Designation System”
2019/02/08
IR情報
IR
Corporate Governance Report
（496KB）
2019/02/06
IR情報
IR
【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED]
（932KB）
2019/01/30
IR情報
IR
Notice Regarding Forecast Revisions of Financial Results and Dividend (Dividend Increase)
（259KB）
2019/01/30
IR情報
IR
Summary of Financial Results for the third quarter 2019
（488KB）
2019/01/16
News
News Release
Takara to Present Oncolytic Virus C-REV Preliminary Data from the Phase I trial Targeting Unresectable Pancreatic Cancer at ASCO-GI 2019 Congress
2018/12/17
IR情報
IR
Notice Regarding Transfer of Mushroom Business
（316KB）
2018/11/14
IR情報
IR
We have posted "Financial Results Presentation".
（684KB）
2018/11/06
IR情報
IR
Consolidated Financial Statements for the Second Quarter Ended September 30, 2018 FY2019 (April 1, 2018 - March 31, 2019)[UNAUDITED]
（728KB）
2018/11/06
IR情報
IR
Summary of Financial Results for the second quarter 2019
（390KB）
2018/10/22
News
News Release
Announcement of Participation in AMED Project “Research and development of core technologies for gene and cell therapy”
2018/10/19
News
News Release
Oncolytic Virus C-REV Data Presentation of Phase II trial Targeting Unresectable or Metastatic Melanoma in Japan at ESMO 2018 Congress
2018/10/15
News
News Release
CAP-LAP Certification of Clinical Testing Laboratory for Takara Bio's Cancer Genetic Testing Business conducted in Osaka University Hospital
2018/09/28
IR情報
IR
【Delayed】Notice Regarding Business Reorganization by Simplified Absorption-type Company Split
（241KB）
2018/09/03
News
News Release
Out-licensing agreement for commercial use of RetroNectin® into Daiichi Sankyo
2018/09/03
IR情報
IR
We have issued "Annual Report 2018".
（2,549KB）
2018/08/22
IR情報
IR
Takara Bio entered into a licensing agreement relating to Oncolytic Virus "Canerpaturev" with Dong-A ST, South Korea
（195KB）
2018/07/31
IR情報
IR
Consolidated Financial Statements for the First Quarter Ended June 30, 2018 FY2019(April 1, 2018-March 31, 2019)[UNAUDITED]
（182KB）
2018/07/31
IR情報
IR
Summary of Financial Results for the first quarter 2019
（109KB）
2018/07/26
News
News Release
Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking
2018/06/08
IR情報
IR
【Delayed】Announcement on revision of Takara Bio Medium-Term Management Plan FY2020
（533KB）
2018/06/08
IR情報
IR
【Delayed】Consolidated Financial Statements for the Year Ended March 31, 2018 FY2018 (April 1, 2017 - March 31, 2018)[UNAUDITED]
（780KB）
2018/05/31
News
News Release
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2018/04/09
News
News Release
Takara Bio entered into an agreement for co-development/exclusive sales of NY-ESO-1・siTCR and CD19 CAR gene therapy with Otsuka
2018/04/06
News
News Release
Announcement on product designation of NY-ESO-1・siTCR gene therapy product for synoviral sarcoma under “SAKIGAKE Designation System” by the Ministry of Health, Labour and Welfare
2018/02/19
News
News Release
Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products
2018/02/13
IR情報
IR
【Delayed】Consolidated Financial Statements for the Third Quarter Ended December 31, 2017 FY2017 (April 1, 2017 - March 31, 2018) [UNAUDITED]
（832KB）
2018/01/30
IR情報
IR
Summary of Financial Results for the third quarter 2018
（96KB）
2018/01/19
News
News Release
First patient enrolled into phase I/II clinical trial of NY-ESO-1・siTCR gene therapy against synovial sarcoma in Japan
2017/12/21
News
News Release
Announcement on investigator-initiated clinical trial of neoadjuvant combination therapy with HF10 and Nivolumab
2017/11/28
IR情報
IR
Consolidated Financial Statements for the Second Quarter Ended September 30, 2017
（1,571KB）
2017/11/06
IR情報
IR
Revision of Consolidated Business Results Forecast ｆor the First Half of the Fiscal Year Ending March 31, 2018
（221KB）
2017/11/06
News
News Release
Exclusive Global License for New Method of iPS Cell Production Obtained
2017/09/27
News
News Release
First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan
2017/08/21
IR情報
IR
Consolidated Financial Statement for the First Quarter Ended June 30, 2017
（891KB）
2017/07/27
IR情報
IR
Summary of Consolidated Financial Statement for the First Quarter Ended June 30, 2017
（367KB）
2017/06/01
News
News Release
Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan
2017/05/29
News
News Release
First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan
2017/05/23
News
News Release
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2017/05/09
IR情報
IR
Consolidated Financial Statement for the year ended March 31, 2017, released on May 9, 2017
（791KB）
2017/05/09
IR情報
IR
Formulation of Takara Bio Medium-Term Management Plan FY2020
（243KB）
2017/03/01
News
News Release
Takara Bio USA Holdings, Inc. completes acquisition of WaferGen Bio-systems, Inc.
2017/01/30
News
News Release
Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan
2017/01/24
News
News Release
Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1・siTCR gene therapy in Japan
2017/01/18
News
News Release
Takara Bio USA Holdings, Inc. completes acquisition of Rubicon Genomics, Inc.
2017/01/11
News
News Release
Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of CAR gene therapy in Japan
2016/12/15
News
News Release
Takara Bio Signs Exclusive License Agreement with Otsuka for the Investigational Cancer Treatment HF10, an Oncolytic Virus
2016/12/15
News
News Release
Takara Bio USA Holdings, Inc. and Rubicon Genomics Announce Merger Agreement
2016/06/21
News
News Release
Takara Bio enters into a license and supply agreement of RetroNectin® with Kite Pharma
2016/05/19
News
News Release
Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology
2016/03/22
News
News Release
Takara Bio grants Cellectis SA a commercial license to use RetroNectin®
2016/02/02
News
News Release
Center for Gene and Cell Processing wins 2016 Facility of the Year Awards
2016/01/27
News
News Release
Establishment of a cell processing facility in “Life Innovation Center (provisional name)” in Tono-machi, Kawasaki city, as the implementation/ industrialization hub for cell therapy and regenerative medicine
2016/01/25
News
News Release
Release of GMP grade PCR enzyme for genetic diagnosis
2016/01/14
News
News Release
Notice of change in the Company Name, consolidated subsidiary, United States-based Clontech Laboratories, Inc.
2015/10/27
News
News Release
HF10 Phase II clinical trial data presented at AACR-NCI-EORTC international conference
2015/09/29
News
News Release
Licensing agreement for manufacturing iPS cells using Sendai virus vector
2015/09/14
News
News Release
HF10 Phase I clinical trial data presented at European Society for Medical Oncology 2015 Congress
2015/08/10
News
News Release
Completion of a new facility and relocation of head office
2015/08/04
News
News Release
The 1st HF10 therapy in Japan was started against solid cancers
2015/07/24
News
News Release
Regenerative medicine based on dental pulp cells
2015/07/23
News
News Release
Takara Bio launches High-performance real-time PCR system
2015/06/17
News
News Release
Acquisition of ISO 9001 certification aiming at improvement in quality of products and services in regenerative medicine fields
2015/06/10
News
News Release
Patent regarding siTCR vector a core technique of gene therapy is granted in the U.S.
2015/06/01
News
News Release
Takara Bio launches culture medium specifically designed for iPS cells for research-use in regenerative medicine field
2015/05/19
News
News Release
Takara Bio is selected for ”Project Focused on Developing Key Evaluation Technology: Evaluation for Industrialization in the Field of Regenerative Medicine”
2015/05/13
News
News Release
Accreditation of the foreign cell processor: Takara Bio can start specific processed cell manufacturing and provide contracted cell processing service to medical institutions
2014/11/10
News
News Release
Acquisition of assets for stem cell-related research products from StemCells Inc.
2014/11/04
News
News Release
License Agreement with iPS Academia Japan Inc.
2014/10/30
News
News Release
Takara Bio receives NEDO Grant to develop mass production of cardiomyocytes derived from human iPS cells
2014/10/27
News
News Release
License agreement for genome editing with Broad Institute
2014/10/01
News
News Release
Marketing of Cellartis™ products started
2014/07/29
News
News Release
Acquisition of stem cell business firm (former Cellartis AB) from Cellectis SA
2014/06/24
News
News Release
Agreement with iHeart Japan Corporation
2014/05/30
News
News Release
Takara Bio reseives NEDO Grant to develop cell manufacturing and processing systems for industrialization of regenerative medicine
2014/05/08
News
News Release
Takara Bio Group’s Mid-term Management Plan
2014/05/01
News
News Release
Takara Bio submitted an Investigational New Drug application for a Phase II clinical trial of HF10 anti-cancer therapy to the Food and Drug Administration
2014/03/13
News
News Release
Clinical research protocol of gene therapy targeting B cell non-Hodgkin Lymphoma was approved by Japanese Ministry
2014/03/03
News
News Release
Takara Bio obtains a governmental grant for commercialization of its TCR gene therapy projects
2014/02/10
News
News Release
Submission of the application for Investigator-initiated Phase I clinical trials of MAGE-A4 TCR gene therapy as Japan’s first genetic immunotherapy for cancer
2014/01/09
News
News Release
Takara Bio releases Mouse Feeder Cell Quantification Kit for quality control of human stem cells
Back to List
IR情報
Clear All
All
決算
業績
適時開示
PR
IR
ガバナンス
株主総会
有価証券報告書
その他
IRトピックス
IR情報
サステナビリティ
Clear All
All
サステナビリティ
Sustainability
ニュース
Clear All
All
ニュースリリース
PR・その他
お知らせ
News
Clear All
All
News Release
Other
Information
Clear All
Results
0
of
0
表示する項目がありません
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
JA
EN
contact
